LifeMD Reports Q1 2026 Financial Results with $8.9 Million Net Loss

LifeMD, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $8.9 million, compared to a loss of $1.6 million in the same period last year. The company's telehealth revenue for the quarter was approximately $50.2 million, a slight decrease of 1% from $50.9 million in Q1 2025. The decline in revenue was attributed to a drop in telehealth product sales, which fell by about $1 million, while subscription revenue saw a modest increase of $280,000. The gross profit margin improved to 88% from 84% year-over-year, driven by a reduction in the cost of telehealth revenue, which decreased by 27% to $5.9 million.

Total operating expenses surged by 21% to approximately $53.2 million, primarily due to a significant increase in selling and marketing expenses, which rose by 34% to $29.9 million. This increase was part of the company's strategy to enhance its sales and marketing initiatives aimed at driving future growth. General and administrative expenses also increased, reflecting higher compensation costs and legal fees. The company’s accumulated deficit as of March 31, 2026, stood at approximately $238.3 million, with total assets of $70.1 million.

LifeMD's operational metrics showed that the company served over 365,000 active patient subscribers as of the end of March 2026, with a total of approximately 1.5 million patients served since inception. The company has been expanding its telehealth offerings, including a recently launched GLP-1 Weight Management Program, which has attracted over 98,000 subscribers. The company also reported an increase in deferred revenue to $12 million, indicating a growing demand for its subscription services.

In terms of strategic developments, LifeMD entered into a Credit Agreement with Citizens Bank, providing a revolving credit facility of up to $30 million to support corporate development initiatives. However, the company reported being out of compliance with one of the financial covenants related to its interest coverage ratio, primarily due to increased marketing expenses. LifeMD has also initiated an At Market Issuance Sales Agreement to raise additional capital through the sale of common stock, with $44.6 million available under this agreement as of March 31, 2026.

Looking ahead, LifeMD expects its existing cash reserves of $34.5 million, along with potential proceeds from the ATM Sales Agreement, to be sufficient to fund its operating expenses and capital requirements for at least the next 12 months. The company continues to focus on expanding its telehealth services and enhancing its technology platform to improve patient care and operational efficiency.